PDD方案治疗初治多发性骨髓瘤的临床研究.pdfVIP

373 doi:10.3969/j.issn.1009-881X.2014.03.007 PDD方案治疗初治多发性骨髓瘤的临床研究 摘要：目的 PDDMM方 2 1481140 mg1 法 26 MMPDD1.3 mg/m 20 mg12458911124 126结果 4.11.12625 96223 8826 2 sCR4 15CR8 31VGPR8 31PR3 12MR2 8SD1 4M PN PDDMM 结论 关键词 中图法分类号R733.3 文献标识码A 文章编号1009-881X(2014)03-0373-03 PDD Regimen for the Treatment of Patients with Initially Diagnosed Multiple Myeloma ZHOU Ya-nan, CHEN Zi-xing, ZHANG Ri, ZHANG Xu-hui, TAO Rui-fang, SHAO Jing-zhang, WU De-pei (The First Affi liated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, Suzhou, Jiangsu, 215006, China) Abstract Objective To evaluate the efficacy of bortezomib combined with liposomal doxorubicin and dexamethasone (PDD) regimen in treating the initially diagnosed multiple myeloma (MM). Methods Twenty-six patients chemotherapy was conducted with PDD regimen every 4 weeks, for 2 to 6 course. Bortezomib was given at the dose of 1.3 mg/m2 on day 1, 4, 8, 11; liposomal doxorubicin 40 mg on day 1; dexamethasone 20 mg on day 12, 45, 89, 1112. The effi cacy and the toxicity were observed. Results After 26 (4.11.1) courses of treatment, the total effi cacy rate was 25 cases (96). After 2 courses of treatment, the overall effi cacy was 23 cases (88). In those cases, the strictest complete remission 4 cases (15), complete remission 8 cases (31), very good partial remission was 4 cases (15), partial remission 3 cases (12), minimal response 2 cases (8), stable disease 1 case (4). Bone marrow plasma cells, serum monoclonal protein were decreased. The m